AU Patent

AU2023248048B2 — Amorphous kinase inhibitor formulations and methods of use thereof

Assigned to Deciphera Pharmaceuticals LLC · Expires 2024-07-25 · 2y expired

What this patent protects

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF ABSTRACT Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRa kinases, …

USPTO Abstract

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF ABSTRACT Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRa kinases, and oncogenic forms thereof.

Drugs covered by this patent

Patent Metadata

Patent number: AU2023248048B2
Jurisdiction: AU
Classification: —
Expires: 2024-07-25
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.